Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Announce Quarterly Sales of $5.71 Billion

Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post $5.71 billion in sales for the current quarter, according to Zacks. Eight analysts have provided estimates for Gilead Sciences’ earnings. The highest sales estimate is $6.00 billion and the lowest is $5.48 billion. Gilead Sciences posted sales of $5.80 billion in the same quarter last year, which suggests a negative year over year growth rate of 1.6%. The firm is scheduled to report its next earnings results on Monday, February 3rd.

According to Zacks, analysts expect that Gilead Sciences will report full year sales of $22.29 billion for the current year, with estimates ranging from $22.05 billion to $22.57 billion. For the next year, analysts anticipate that the business will report sales of $22.43 billion, with estimates ranging from $20.51 billion to $23.50 billion. Zacks’ sales averages are a mean average based on a survey of analysts that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.01. The firm had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 earnings per share.

A number of analysts have recently issued reports on GILD shares. Royal Bank of Canada raised shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 target price for the company in a research note on Monday, July 29th. Morgan Stanley set a $75.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Friday, October 25th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Citigroup set a $78.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $78.87.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 608 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at $1,750,191.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 5,677 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the completion of the transaction, the executive vice president now owns 21,521 shares of the company’s stock, valued at $1,362,494.51. The disclosure for this sale can be found here. Insiders sold 17,288 shares of company stock valued at $1,108,682 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Advisors Preferred LLC bought a new position in Gilead Sciences in the second quarter worth about $26,000. First Financial Corp IN increased its holdings in shares of Gilead Sciences by 286.4% during the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 401 shares in the last quarter. Legacy Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter valued at about $37,000. Venturi Wealth Management LLC acquired a new position in shares of Gilead Sciences during the third quarter valued at about $40,000. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter valued at about $46,000. Institutional investors and hedge funds own 80.03% of the company’s stock.

Shares of Gilead Sciences stock traded up $1.26 on Thursday, hitting $65.07. 6,773,400 shares of the company traded hands, compared to its average volume of 6,297,733. The stock has a market capitalization of $80.73 billion, a P/E ratio of 10.58, a price-to-earnings-growth ratio of 3.39 and a beta of 1.09. Gilead Sciences has a 52 week low of $60.32 and a 52 week high of $72.90. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.87 and a current ratio of 2.96. The business has a 50-day simple moving average of $64.01 and a 200 day simple moving average of $65.29.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, December 12th. This represents a $2.52 annualized dividend and a dividend yield of 3.87%. Gilead Sciences’s payout ratio is currently 40.98%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Bid-Ask Spread

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.